Genomic cancer driver study reveals new clues to why some prostate cancers become aggressive
Why do some prostate cancers grow slowly for years, while others progress quickly to life-threatening metastatic disease? An international team of researchers co-led by the Ontario Institute for Cancer Research (OICR) and the University of Copenhagen has uncovered new clues in the genomes of prostate cancers.
An international research team, co-led by the Ontario Institute for Cancer Research and the University of Copenhagen, has uncovered new insights into the genomic drivers of prostate cancer. By analyzing the entire genomes of nearly 1,000 prostate tumors, the researchers identified 97% that carried at least one genetic alteration linked to cancer, including known and previously unrecognized cancer drivers.
The study also revealed four distinct genomic subtypes of prostate cancer, two of which were associated with a significantly higher risk of metastasis. Additionally, the researchers identified potential targets for existing cancer drugs in nearly one-quarter of the tumors, suggesting opportunities for future targeted treatments.
The findings could help better predict which patients are at risk of aggressive disease and optimize treatment strategies based on individual genomic profiles.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
